A phase II safety and efficacy study of bavituximab plus docetaxel in patients with locally advanced or metastatic breast cancer.

Trial Profile

A phase II safety and efficacy study of bavituximab plus docetaxel in patients with locally advanced or metastatic breast cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Bavituximab (Primary) ; Docetaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Peregrine Pharmaceuticals
  • Most Recent Events

    • 27 Aug 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
    • 27 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 May 2010 New progression-free survival data will be presented at ASCO on June 5 2010 (Abstract no. 1042), as reported in a Peregrine Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top